Essential Pharma Strengthens Global Capabilities with New Appointments in Switzerland


ZUG, Switzerland, April 6, 2022 /PRNewswire/ — Essential Pharma, an international specialty pharma group focused on maintaining access to well-established, patient-essential “at-risk” products across multiple therapeutic areas, announces the global expansion of its senior team with two new recruits in Switzerland. Fabio Zeppegno was appointed head of global supply chain, and Laura Castagno joins as Senior Director of Quality Assurance (QA), Regulatory Affairs (RA) and Pharmacovigilance (PV).

Steen Vangsgaard, CEO commented: “I am delighted to welcome Fabio and Laura who are joining the company at an exciting time as we continue to expand and grow our product portfolio. They will help us pursue our ambition to become one of the world’s leading suppliers of essential risk medicines. where there is a high unmet clinical need Fabio and Laura will be central to the future development of our business in Switzerlandwhich is central to our growth ambitions, and I look forward to working with them as we advance our operational and business infrastructure while maintaining the highest standards across our growing business.”

Fabio Zeppegno joined as Head of Global Supply Chain. He has over 15 years of diverse experience in supply chain roles. Most recently, Fabio spent 7 years at Teva Pharmaceuticals where he worked as Associate Director of Supply Chain and managed the successful creation of the company’s global biologics and specialty supply chain business in Switzerland. Fabio led the Supply Chain Planning and Project Lifecycle Management execution function, which successfully integrated the portfolio into the Swiss entity for several important Teva products, including the global launch of new biological products as well as several product divestitures. Fabio holds an MSc in Procurement, Logistics and Supply Chain from the University of Salford and is a chartered member of CIPS (Chartered Institute of Procurement and Supply).

Laura Castagno was appointed Senior Director of QA, RA and PV. She has over 25 years of experience in the pharmaceutical industry and joins the team at Corza Medical, a global manufacturer of innovative surgical technologies, where she worked as Director of Pharmacovigilance, Regulatory, Quality and medical information. Previously, Laura was Director of Global Regulatory Affairs and Quality at Primex Pharmaceuticals, where she managed quality and regulatory activities for registered medicines in over 50 countries around the world. In this position, she was also the person responsible for the distribution and PV activities at Switzerland. Laura holds a master’s degree in chemistry and pharmaceutical technology from the University of Torino (Italy) and holds a master’s degree in patents and intellectual property from the University of Milano (Italy).

About Essential Pharma

Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to well-established, patient-essential “risky” products across multiple therapeutic areas. The group has been an important and valued partner of healthcare providers for over 20 years by enabling patients to access medicines that would otherwise not be available.

Essential Pharma operates globally in over 20 countries, providing a portfolio of over 150 essential medicines across multiple therapeutic areas. Essential Pharma’s growth strategy is based on the identification and acquisition of mature products at risk from large pharmaceutical groups seeking to rationalize their product portfolios.

It is a trusted partner for several pharmaceutical companies of all sizes, with a proven track record in integrating assets, managing complex technologies and product transfers while ensuring a continuous and sustainable supply to patients.

Essential Pharma maintains strong relationships with partners at ten manufacturing sites across the EU and US to ensure the continued manufacture of its products to the highest regulatory standards.

Essential Pharma’s growth strategy is supported by Gyrus Capital, an investment firm dedicated to transformational investments in long-term sustainable growth sectors, including healthcare.

For more information, visit


Essential pharmaceuticals
Steen Vangsgaard, CEO
Tel: +44(0)1784 477 167
E-mail: [email protected]

MEDiSTRAVA Consulting (for Essential Pharma)
David DibleFrazer Room, Evelyne McCormack
Tel: +44 (0) 20 3928 6900
E-mail: [email protected]

SOURCE Essential Pharma


About Author

Comments are closed.